Momelotinib momentum makes GSK's gain Gilead's loss

23 June 2022

When Sierra Oncology (Nasdaq: SRRA) announced positive top-line results from the MOMENTUM trial earlier this year, certain execs at Gilead Sciences (Nasdaq: GILD) may have had a sinking feeling.

The study provided late-stage validation of what researchers had long suspected, that the oral JAK1, JAK2 and ACVR1 blocker momelotinib has huge potential in myelofibrosis.

The news sent Sierra stock soaring and attracted the interest of GSK (LSE: GSK) chief commercial officer Luke Miels, who negotiated a $1.9 billion purchase price for the firm in April.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK